Mutual Advisors’s 10x Genomics TXG Stock Holding History

Mutual Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,274	Closed	-$187K	–	1337
2025 Q2	$187K	Buy	+13,274	New	+$121K	﹤0.01%	1139

Other funds holding TXG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

QCM

Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Mutual Advisors's TXG Position: Q3 2025 in Review

Mutual Advisors sold out of 10x Genomics (TXG) in Q3 2025, closing a stake of 13,274 shares — an estimated $187K sold.

Mutual Advisors first reported a position in TXG in Q2 2025 and held it in 1 quarter. The position peaked at $187K in Q2 2025. 317 funds tracked by Wall St. Rank hold TXG as of Q3 2025.

Mutual Advisors reported no remaining 10x Genomics position as of Q3 2025 after selling out during the quarter.
Mutual Advisors sold 13,274 10x Genomics shares in Q3 2025, an estimated $187K.
Mutual Advisors first reported a position in 10x Genomics in Q2 2025 and held it in 1 quarter.
Mutual Advisors's 10x Genomics position peaked at $187K in Q2 2025.
317 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2025.

Based on Mutual Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.